

**BCBe/05/Neb-Pao/088**

**Nebivolol vs Metoprolol in hypertensive patients with peripheral artery occlusive disease" (PAOD)**

**This study is currently recruiting patients**

**Sponsor:** Berlin Chemie AG

**Intervention:** Nebivolol 5 mg daily or Metoprolol 95 mg daily

**Condition:** Stage I hypertensive patients with PAOD (peripheral artery occlusive disease) Fontaine's stage II

**Study type & design:** double-blind, parallel group and active controlled

**Main criteria for inclusion:**

- 1 Male patients 30 years to 80 years or female postmenopausal patients up to 80 years
- 2 Stage I hypertension according to JNC (SBP 140-159 mmHg or DBP 90-99 mmHg) or current treatment with antihypertensive
- 3 PAOD Fontaine's stage IIa or IIb with
  - -a history of typical claudication for at least 6 months with documented lesions by duplex sonography or angiography within the last 12 months prior to inclusion
  - -a ankle-brachial pressure index (ABPI) < 0.90

**Main criteria for exclusion**

- 1 PAOD with rest pain or leg ulcer or gangrene
- 2 Any concomitant disease limiting the exercise capacity of the patient
- 3 Standardized exercise training during the study or walking exercises during the study exceeding the all-day habits of the patient as compared to the patient's habits prior to study inclusion
- 4 Poorly controlled diabetes mellitus (HbA1c > 8.5 %)